粪菌移植:儿科医生须知
粪菌移植(FMT)是将健康供体的整个微生物群落转移给受者以改善或治愈特定疾病。当前证据强烈支持FMT用于治疗艰难梭菌感染,治愈率约80%至90%。本临床报告支持北美与欧洲儿科胃肠病学、肝病学和营养学会的联合声明,旨在为普通儿科医生提供广泛概述,以便为寻求FMT治疗儿童疾病的家庭提供适当指导。
要点
- FMT对艰难梭菌感染的治愈率约80%至90%。
- FMT在其他与肠道微生物群紊乱相关疾病中的角色受到越来越多关注。
- 本报告支持北美与欧洲儿科胃肠病学、肝病学和营养学会的联合声明。
核心结论
- 当前证据强烈支持FMT用于治疗艰难梭菌感染,治愈率约80%至90%。
- FMT作为其他与肠道微生物群紊乱相关疾病的潜在治疗干预受到越来越多关注。
- 本临床报告支持北美与欧洲儿科胃肠病学、肝病学和营养学会的联合声明。
研究设计与样本
- 本临床报告为普通儿科医生提供FMT的广泛概述,以指导寻求FMT治疗儿童疾病的家庭。
主要发现
- FMT治疗艰难梭菌感染的治愈率约为80%至90%。
- FMT受到越来越多关注用于炎症性肠病、自闭症谱系障碍和肥胖等与肠道微生物群紊乱相关的疾病。
关键数值与推荐
- FMT对艰难梭菌感染的治愈率约为80%至90%。
临床怎么用
- 普通儿科医生应了解FMT的当前证据,以便为寻求FMT治疗儿童疾病的家庭提供适当指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fecal microbiota transplantation (FMT) involves the delivery of an entire microbial community from a healthy donor to a recipient with the intention of ameliorating or curing a specific disease. Current evidence strongly supports a role for FMT in the treatment of Clostridiodes difficile infection, with cure rates of approximately 80% to 90%. This success has led to increasing attention for FMT as a potential therapeutic intervention for other conditions associated with disturbances of the intestinal microbiome, including inflammatory bowel diseases, autism spectrum disorder, and obesity. This clinical report endorses the joint society statement by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition and is meant to provide the general pediatrician with a broad overview to enable appropriate guidance to families seeking FMT as treatment of a child's condition.
引用
- Oliva-Hemker M, Kahn SA, Steinbach WJ, et al. Fecal Microbiota Transplantation: Information for the Pediatrician. Pediatrics. 2023. PMID: 37981872. doi:10.1542/peds.2023-062922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。